---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-039661"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:45:33.977714+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech Q2 net loss $11.5M ($0.37/sh); cash $60.6M; Phase 3 protocol submitted to FDA

## Summary
- Net loss of $11.5M ($0.37 per share) vs. $5.8M ($0.20 per share) in Q2 2022.
- R&D expenses rose to $8.0M from $3.8M; G&A rose to $4.7M from $3.3M.
- Cash and equivalents $60.6M; management says sufficient for 12 months.
- Submitted final Phase 3 VERSATILE-003 protocol to FDA to start Q4 2023.
- VERSATILE-002 interim data showed 12-month OS rate of 87% with favorable safety.

## SEC filing metadata
- accession: 0001140361-23-039661
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036123039661/0001140361-23-039661-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036123039661/brhc20057492_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-039661
- JSON: https://secwatch.observer/filing/0001140361-23-039661.json
- Plain text: https://secwatch.observer/filing/0001140361-23-039661.txt

## Key facts
- Earnings Releases
  PDS Biotechnology Corp reported for the three and six months ended June 30, 2023 results: net income Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and dilute, EPS ($0.37) per basic share and diluted share.
  - Period: for the three and six months ended June 30, 2023
  - Net income: Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and dilute
  - EPS: ($0.37) per basic share and diluted share
  - Result: reported results
  source text: Net loss for the three months ended June 30, 2023 was approximately $11.5 million, or ($0.37) per basic share and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472091/000114036123039661/0001140361-23-039661-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.